ReviewNature reviews. Cancer2025
Metabolic interplays between the tumour and the host shape the tumour macroenvironment.
Review in Nature reviews. Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Metabolic Bottlenecks and Opportunities: Reshaping the Tumor Microenvironment for Cancer Immunotherapy.Cells · 2026Review
- Metabolic adaptations of the tumor macroenvironment and their role in cancer progression and survivorship.Genes & development · 2026Review
- Lactate-to-albumin ratio as an independent predictor of short- and long-term mortality in ICU patients with malignant tumors: A retrospective cohort study.Oncology letters · 2026Article
- Synergistic Probe Combining Lysosome Anchoring and Tumor Defense System Targeting for Precise Tumor Visualization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Catalytic profiling of extracellular vesicles maps altered cancer metabolism.Nature nanotechnology · 2026Article
- Predictive Value of Peripheral Blood Inflammatory Markers and Nutritional Indices for Survival in Young Patients with Advanced Non-Small Cell Lung Cancer: Construction of a Nomogram.Current oncology (Toronto, Ont.) · 2026Article
- Combined Pharmacologic and Nutritional Modulation of High-Fat Diet-Associated Tumor-Supportive Features in Prostate Cancer Models.Biomolecules · 2026Article
- A Radioresistant-Tumor-Targeted Nanoparticle for X-Ray-Controlled Nitric Oxide Release to Potentiate Radiotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Circulating Amino Acid Network Remodeling Reveals Systemic Metabolic Reprogramming Predictive of Colorectal Cancer Recurrence and Metastasis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Metabolic Crosstalk Between Host and Tumor as a Circuit of Resilience in Cancer Therapy.Cells · 2026Review
- HBx-mediated GPT2 suppression promotes liver cancer development by downregulating ADH1A.Cancer biology & medicine · 2026Article
- Dynamic machine learning model integrating resting energy expenditure for predicting postoperative complications after gastrectomy for gastric cancer.Journal of cancer research and clinical oncology · 2026Article
- Decoding cancer across scales with metabolomics.Nature reviews. Cancer · 2026Review
- [18 F]FDG PET unveils a cachexia-specific multiorgan metabolic phenotype and identifies patients with poor prognosis in locally advanced rectal cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Association of Underweight, Sarcopenia, and Cancer Cachexia with Survival Outcomes in Hypopharyngeal Cancer Radiotherapy.Cancers · 2026Article
- Cuproptosis meets sonodynamics: a nanomedicine platform for multimodal cancer therapy.RSC advances · 2026Review
- Identification of biomarkers for non-invasive diagnosis and risk stratification in prostate cancer using NMR-based metabolomics and machine learning.NPJ precision oncology · 2026Article
- Preoperative lymphocyte-albumin-monocyte index as an inflammation- and nutrition-based predictor of overall survival in triple-negative breast cancer: A retrospective cohort study.Oncology letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Metabolic reprogramming of cancer cells and the tumour microenvironment are pivotal characteristics of cancers, and studying these processes offer insights and avenues for cancer diagnostics and therapeutics. Recent advancements have underscored the impact of host systemic features, termed macroenvironment, on facilitating cancer progression. During tumorigenesis, these inherent features of the host, such as germline genetics, immune profile and the metabolic status, influence how the body responds to cancer. In parallel, as cancer grows, it induces systemic effects beyond the primary tumour site and affects the macroenvironment, for example, through inflammation, the metabolic end-stage syndrome of cachexia, and metabolic dysregulation. Therefore, understanding the intricate metabolic interplay between the tumour and the host is a growing frontier in advancing cancer diagnosis and therapy. In this Review, we explore the specific contribution of the metabolic fitness of the host to cancer initiation, progression and response to therapy. We then delineate the complex metabolic crosstalk between the tumour, the microenvironment and the host, which promotes disease progression to metastasis and cachexia. The metabolic relationships among the host, cancer pathogenesis and the consequent responsive systemic manifestations during cancer progression provide new perspectives for mechanistic cancer therapy and improved management of patients with cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.